As a highlight of BIOHK2025—Asia's premier biotechnology conference and exhibition—Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, will partner with the Hong Kong Biotechnology Association to present a satellite forum themed "Exploring the Frontiers of AI in Drug Discovery, Development, and Beyond", entitled “Towards Pharmaceutical Superintelligence.”

Industrial emissions of sulfur dioxide (SO₂) and nitrogen oxides (NOₓ) in production and daily life contribute to acid rain formation, which degrades soil and aquatic ecosystems while impairing human respiratory health.

Short bowel syndrome (SBS) is a severe condition marked by malabsorption of nutrients and dependence on intravenous nutrition. In a recent study, researchers from Japan explored how glucagon-like peptide-2 (GLP-2) analog therapy transforms the intestinal environment at the cellular level. Using single-cell analysis and microbiome profiling, they revealed that GLP-2 analog treatment promotes gut remodeling, enhances nutrient absorption, reduces inflammation, and reshapes the microbiome—offering key insights for improving SBS therapy.

Bulimia nervosa is an eating disorder that often goes untreated owing to limited access to specialist care. To address this, researchers tested a guided internet-based cognitive behavioral therapy program for women with bulimia that could be delivered online. They found that online therapy reduced binge eating and purge behaviors and achieved improved remission rates compared to usual care, offering a promising way to make effective treatment more accessible for people with limited clinic access.